Bavarian Nordic A/S Consolidates Vaccine Manufacturing in Denmark

Bavarian Nordic A/S announced that it will consolidate its manufacturing activities in Kvistgaard, Denmark with an aim to optimize productivity and profitability. As part of this consolidation, the Company will prepare the Kvistgaard facility for the future commercial production of its prostate cancer vaccine, PROSTVAC and also transfer its production of clinical trial material to the facility. Consequently, the Company will close its operations in Berlin, Germany where it has been producing clinical trial material for its MVA-BN-based vaccine candidates. During 2012, the Company has steadily improved the efficiency in the manufacturing of IMVAMUNE smallpox vaccine at its commercial-scale facility in Kvistgaard. Further work is ongoing to improve the manufacturing process and the productivity, thus seeking to further improve the profitability of the current and future expected contracts with the United States Government to manufacture and deliver IMVAMUNE. The Company decided to prepare the facility for the future commercial production of PROSTVAC as well as to move its production of clinical trial material for the Company's MVA-BN-based development projects. At the Kvistgaard facility, functions to support the production development of PROSTVAC are already in place and thus the preparatory work requires only moderate investments.